查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703263

子宮肌瘤治療藥物市場－全球產業規模、佔有率、趨勢、機會和預測（按藥物類別、類型、最終用戶、地區和競爭情況細分，2020-2030 年）

Uterine Fibroid Treatment Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Type, By End User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球子宮肌瘤治療藥物市場價值為 48.5 億美元，預計到 2030 年將以 4.40% 的年複合成長率(CAGR) 穩步成長。

市場概覽
預測期 2026-2030
2024年市場規模 48.5億美元
2030年市場規模 62.9億美元
2025-2030 年複合年成長率 4.40%
成長最快的領域 黏膜下肌瘤
最大的市場 北美洲

市場擴張受到多種關鍵因素的推動，包括子宮肌瘤在全球範圍內的患病率不斷上升、對非手術治療方案的偏好日益增加、藥物研究的進步以及醫療服務的可及性不斷提高。子宮肌瘤，也稱為平滑肌瘤，是影響育齡婦女最常見的良性腫瘤之一，常與月經過多、骨盆腔疼痛和生育併發症有關。

認知的不斷提高、診斷方法的改進以及治療管道的擴大加速了藥物治療的採用。這在促性腺激素釋放激素 (GnRH) 拮抗劑、基於黃體素的療法和非荷爾蒙替代品的使用日益增多方面表現得尤為明顯，反映了患者對非侵入性療法而非外科手術的偏好發生了更廣泛的轉變。持續的藥物創新、更高的監管批准率以及不斷擴大的保險覆蓋範圍繼續支持市場的積極前景，特別是在子宮肌瘤發病率激增和醫療服務改善的地區。

關鍵市場促進因素

子宮肌瘤盛行率上升

主要市場挑戰

長期療效和安全性數據有限

主要市場趨勢

聯合療法的出現

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：臨床試驗分析

第6章：全球子宮肌瘤治療藥物市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物類別（促性腺激素釋放激素 (Gnrh) 激動劑、促性腺激素釋放激素 (Gnrh) 拮抗劑、黃體素釋放子宮內避孕器 (Iud) 及避孕藥、非荷爾蒙藥物、其他）
    • 依類型（漿膜下子宮肌瘤、壁內子宮肌瘤、黏膜下子宮肌瘤、帶蒂子宮肌瘤）
    • 按最終用戶（醫院藥房、零售藥房、其他）
    • 按地區
    • 按公司分類（2024）
  • 產品市場圖

第7章：北美子宮肌瘤治療藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第8章：歐洲子宮肌瘤治療藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第9章：亞太子宮肌瘤治療藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第10章：南美子宮肌瘤治療藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章：中東和非洲子宮肌瘤治療藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第 12 章：市場動態

  • 驅動程式
  • 挑戰

第13章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 14 章：政策與監管格局

第 15 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 16 章：競爭格局

  • Myovant Sciences Ltd
  • Pfizer Inc
  • Abbvie Inc
  • Ferring BV
  • AstraZeneca
  • Bayer AG
  • Amring Pharmaceuticals Inc
  • Watson Pharma Pvt Ltd

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 17232

Global Uterine Fibroid Treatment Drugs Market was valued at USD 4.85 billion in 2024 and is projected to register steady growth at a compound annual growth rate (CAGR) of 4.40% through 2030.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.85 Billion
Market Size 2030USD 6.29 Billion
CAGR 2025-20304.40%
Fastest Growing SegmentSubmucosal Fibroids
Largest MarketNorth America

Market expansion is being driven by several key factors, including the rising global prevalence of uterine fibroids, increasing preference for non-surgical treatment options, advancements in pharmaceutical research, and greater accessibility to healthcare services. Uterine fibroids, also referred to as leiomyomas, are among the most common benign tumors affecting women of reproductive age and are often associated with heavy menstrual bleeding, pelvic pain, and fertility complications.

Growing awareness, improved diagnostic practices, and expanded access to treatment have accelerated the adoption of pharmacological therapies. This is particularly evident in the increasing use of gonadotropin-releasing hormone (GnRH) antagonists, progestin-based regimens, and non-hormonal alternatives, reflecting a broader shift in patient preference toward non-invasive therapies over surgical procedures. Ongoing drug innovations, higher regulatory approval rates, and expanding insurance coverage continue to support the market's positive outlook, especially in regions witnessing a surge in fibroid incidence and improved access to care.

Key Market Drivers

Rising Prevalence of Uterine Fibroids

The increasing global prevalence of uterine fibroids is a primary growth driver for the market. These benign pelvic tumors, although non-cancerous, are widespread among women of reproductive age. Due to their frequently asymptomatic nature, actual prevalence is likely underreported. Studies indicate a wide prevalence range from 4.5% to 68.6%, influenced by variables such as diagnostic methods, population demographics, and healthcare availability.

As the number of diagnosed cases continues to rise, so does the demand for effective pharmacological treatment. Factors such as late pregnancies, hormonal imbalances, and a global increase in obesity contribute significantly to the growing incidence of uterine fibroids. For instance, in 2022, one in every eight individuals globally was affected by obesity. Since 1990, obesity rates have more than doubled in adults and quadrupled in adolescents, with 2.5 billion adults classified as overweight, including 890 million with obesity. These health trends further amplify the burden of uterine fibroids and underscore the demand for scalable, non-invasive treatment solutions.

Key Market Challenges

Limited Long-Term Efficacy and Safety Data

While pharmaceutical treatments for uterine fibroids have demonstrated notable effectiveness in managing symptoms, concerns remain regarding their long-term safety and efficacy. Many clinical studies feature relatively short follow-up periods, limiting insights into extended use and sustained outcomes. To ensure continued patient trust and optimize treatment strategies, robust long-term clinical data is essential. Such data will help address safety concerns, inform regulatory decisions, and guide healthcare providers in making evidence-based therapeutic choices.

Key Market Trends

Emergence of Combination Therapies

The market is witnessing a growing interest in combination therapy approaches, integrating uterine fibroid drugs with minimally invasive procedures or complementary hormonal treatments. These integrated solutions offer the potential for enhanced symptom relief, improved patient outcomes, and a more personalized treatment experience.

Combination therapies are especially promising for patients with varying fibroid types, sizes, or symptoms, allowing for tailored care strategies that target fibroids through multiple mechanisms. This approach not only improves therapeutic efficacy but also reduces the likelihood of recurrence, positioning combination treatment as a compelling solution in the evolving landscape of uterine fibroid care.

Key Market Players

  • Myovant Sciences Ltd
  • Pfizer Inc
  • Abbvie Inc
  • Ferring BV
  • AstraZeneca
  • Bayer AG
  • Amring Pharmaceuticals Inc
  • Watson Pharma Pvt Ltd

Report Scope:

In this report, the Global Uterine Fibroid Treatment Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uterine Fibroid Treatment Drugs Market, By Drug Class:

  • Gonadotropin-Releasing Hormone (Gnrh) Agonists
  • Gonadotropin-Releasing Hormone (Gnrh) Antagonists
  • Progestin-Releasing Intrauterine Device (Iud) & Contraceptives
  • Non-Hormonal Medications
  • Others

Uterine Fibroid Treatment Drugs Market, By Type:

  • Subserosal Fibroids
  • Intramural Fibroids
  • Submucosal Fibroids
  • Pedunculated Fibroids

Uterine Fibroid Treatment Drugs Market, By End User:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Uterine Fibroid Treatment Drugs Market, By region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Competitive Landscape

Uterine Fibroid Treatment Drugs Market.

Available Customizations:

Global Uterine Fibroid Treatment Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Uterine Fibroid Treatment Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 6.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 6.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2024)
  • 6.3. Product Market Map

7. North America Uterine Fibroid Treatment Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Type
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End User
    • 7.3.2. Mexico Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End User
    • 7.3.3. Canada Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End User

8. Europe Uterine Fibroid Treatment Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Type
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End User
    • 8.3.2. Germany Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End User
    • 8.3.3. United Kingdom Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End User
    • 8.3.4. Italy Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Spain Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By End User

9. Asia-Pacific Uterine Fibroid Treatment Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Type
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End User
    • 9.3.2. India Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End User
    • 9.3.3. South Korea Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End User
    • 9.3.4. Japan Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Class
        • 9.3.4.2.2. By Type
        • 9.3.4.2.3. By End User
    • 9.3.5. Australia Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Class
        • 9.3.5.2.2. By Type
        • 9.3.5.2.3. By End User

10. South America Uterine Fibroid Treatment Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Type
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Uterine Fibroid Treatment Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Argentina Uterine Fibroid Treatment Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By End User
    • 10.3.3. Colombia Uterine Fibroid Treatment Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By End User

11. Middle East and Africa Uterine Fibroid Treatment Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Type
    • 11.2.3. By End User
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Type
        • 11.3.1.2.3. By End User
    • 11.3.2. Saudi Arabia Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Type
        • 11.3.2.2.3. By End User
    • 11.3.3. UAE Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Type
        • 11.3.3.2.3. By End User
    • 11.3.4. Kuwait Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Drug Class
        • 11.3.4.2.2. By Type
        • 11.3.4.2.3. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Product Launches
  • 13.3. Mergers & Acquisitions

14. Policy & Regulatory Landscape

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Product

16. Competitive Landscape

  • 16.1. Myovant Sciences Ltd
    • 16.1.1. Business Overview
    • 16.1.2. Product & Service Offerings
    • 16.1.3. Recent Developments
    • 16.1.4. Financials (If Listed)
    • 16.1.5. Key Personnel
    • 16.1.6. SWOT Analysis
  • 16.2. Pfizer Inc
  • 16.3. Abbvie Inc
  • 16.4. Ferring BV
  • 16.5. AstraZeneca
  • 16.6. Bayer AG
  • 16.7. Amring Pharmaceuticals Inc
  • 16.8. Watson Pharma Pvt Ltd

17. Strategic Recommendations

18. About Us & Disclaimer